David Hovland
General Counsel at ELEDON PHARMACEUTICALS, INC.
David Hovland active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ELEDON PHARMACEUTICALS, INC. | General Counsel | 2021-04-18 | - |
Career history of David Hovland
Former positions of David Hovland
| Companies | Position | Start | End |
|---|---|---|---|
| UROVANT SCIENCES LTD. | General Counsel | 2018-03-31 | 2021-03-31 |
| ALLERGAN PLC | General Counsel | 2014-12-31 | 2017-12-31 |
| Corporate Officer/Principal | 2009-12-31 | 2014-12-31 | |
| AMGEN INC. | General Counsel | 2005-12-31 | 2009-12-31 |
| ALLERGAN PLC | Corporate Officer/Principal | 1998-12-31 | 2001-12-31 |
Training of David Hovland
| University of California, Los Angeles | Doctorate Degree |
| University of California, Berkeley | Undergraduate Degree |
Statistics
International
| United States | 5 |
| United Kingdom | 2 |
| Ireland | 2 |
Operational
| General Counsel | 4 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| ELEDON PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Urovant Sciences Ltd.
 Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- David Hovland
- Experience
